ASCO in Action

ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.

To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.

September 14, 2022

UPDATE: On September 14, 2022, the House of Representatives passed the Improving Seniors’ Timely Access to Care Act (H.R. 3173) by voice vote on the House floor. The bill now moves to the Senate. This remains a critical moment when your Senators need to hear your support for this legislation. Please ask them to pass this bill into law—it takes seconds using the ACT Network. 

September 13, 2022

The American Society of Clinical Oncology (ASCO) issued a new position statement on Medicare billing for split or shared (split/shared) evaluation and management (E/M) services. The statement summarizes ASCO’s concerns about changes to split/shared E/M services and makes recommendations to better align Medicare coding for E/M services with the care that beneficiaries with cancer need.

September 13, 2022

In a letter to the Centers for Medicare & Medicaid Services (CMS), the Association for Clinical Oncology (ASCO) comments on provisions in the 2023 Medicare Physician Fee Schedule (MPFS) and Quality Payment Program (QPP) proposed rule that would impact cancer care for Medicare beneficiaries.

September 12, 2022

“President John F. Kennedy’s historic speech that inspired our nation and an entire generation of Americans to achieve manned space exploration underscored the courage and commitment it would take to accomplish this then-audacious goal: ‘We choose to go to the moon in this decade and do the other things, not because they are easy, but because they are hard.’

September 8, 2022

This September leadership and advocates from the Association of Clinical Oncology (ASCO) are set to participate in various events commemorating Childhood Cancer Awareness Month.

September 7, 2022

The first 10 participants in the new Leadership Programme for Women in Oncology have been announced. The program, a joint endeavour from ASCO and City Cancer Challenge Foundation (C/Can), seeks to address the specific challenges and barriers faced by women leaders in oncology and strengthen the leadership mindsets and skills of women working to improve access to equitable, quality cancer care in C/Can cities.

September 6, 2022

Medicare providers are facing significant reimbursement cuts starting January 1. The 2023 Medicare Physician Fee Schedule proposal jeopardizes the financial stability of many oncology practices by proposing a cut to the Medicare conversion factor of approximately 4.5%. Urge Congress to pass important changes that will provide practices with short-term fiscal stability, while simultaneously laying the foundation for long-term payment reforms.  

September 1, 2022

The Centers for Medicare & Medicaid Services (CMS) released a Request for Information seeking public comment on various aspects of the Medicare Advantage (MA) program as CMS works toward establishing more equitable, high-quality care in MA. The Association for Clinical Oncology (ASCO) submitted a response to the agency on a variety of issues including health equity, expanding access to coverage and care, promoting person-centered care, and supporting sustainability and affordability. Some of the issues addressed in ASCO’s comments are summarized here.

August 26, 2022

On August 26, 2022, the Food and Drug Administration approved pemigatinib (Pemazyre, Incyte Corporation) for adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement.

August 26, 2022

On August 25, 2022, the Centers for Medicare & Medicaid Services (CMS) issued a final rule indefinitely delaying the start of the Radiation Oncology Model. CMS will establish new start and end dates for the model through future rulemaking, which may also modify the model’s design. CMS will propose a new start date for the model at least six months prior to the proposed date.

August 24, 2022

On August 24, 2022, the Food and Drug Administration approved ibrutinib (Imbruvica, Pharmacyclics LLC) for pediatric patients ≥ 1 year of age with chronic graft versus host disease (cGVHD) after failure of 1 or more lines of systemic therapy. Formulations include capsules, tablets, and oral suspension. 

August 19, 2022

In July 2022, ASCO and the African Organisation for Research and Training in Cancer (AORTIC) signed a memorandum of understanding committing the two organizations to collaborate to advance cancer research in Africa.  

August 16, 2022

The Inflation Reduction Act extends Affordable Care Act (ACA) tax credit subsidies, allows Medicare to negotiate prescription drug prices, places inflationary caps on price increases for Medicare Part B and Part D drugs, and limits Medicare beneficiaries’ out-of-pocket spending on Part D prescription drugs.

August 16, 2022

In response to the recent Supreme Court decision, ASCO has developed and compiled resources related to reproductive health in patients with cancer to help members navigate changes and ensure patient access to high-quality cancer care.

August 15, 2022

The American Medical Association (AMA) recently released new guidelines for reporting Evaluation and Management (E/M) services, which are to go into effect on January 1, 2023. 

Pages